These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9799069)

  • 1. The dependency of calcium set point on basal plasma calcium in dialysis patients: a better explanation for the discrepancies regarding its link with PTH secretion than methodological differences.
    Hardy-Yverneau P; Shenouda M; Moriniere P; Legallais C; Brazier M; Achard J; Fournier A
    Clin Nephrol; 1998 Oct; 50(4):236-46. PubMed ID: 9799069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
    Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
    Malberti F; Surian M; Cosci P
    Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
    Malberti F; Surian M; Cosci P
    Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
    Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
    Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Rodriguez AP; Felsenfeld AJ
    J Bone Miner Res; 1997 Mar; 12(3):347-55. PubMed ID: 9076577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-PTH relationship in dialysis patients: the pitfalls of using a constant dialysate calcium concentration during the dynamic tests.
    De Cristofaro V; Samà F; Pagliari B; Colturi C; Sidoti A; Masa A; Filippini M; Comelli M; Pedrini L
    Clin Nephrol; 1998 Feb; 49(2):113-20. PubMed ID: 9524782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy.
    Schindler S; Mannstadt M; Urena P; Segre GV; Stein G
    Clin Nephrol; 2004 Apr; 61(4):253-60. PubMed ID: 15125031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
    Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
    J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
    Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia.
    Jara A; Chacón C; Valdivieso A; Aris L; Jalil R; Felsenfeld AJ
    Nephrol Dial Transplant; 2001 May; 16(5):1009-16. PubMed ID: 11328908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.
    Gardin JP; Patron P; Fouqueray B; Prigent A; Paillard M
    Miner Electrolyte Metab; 1988; 14(4):221-8. PubMed ID: 2850460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo studies of parathyroid gland function in secondary hyperparathyroidism.
    Salusky IB; Goodman WG
    Adv Nephrol Necker Hosp; 1996; 25():289-302. PubMed ID: 8717632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S; Akizawa T; Kurokawa K; Marumo F; Sakai O; Arakawa M; Morii H; Seino Y; Ogata E; Ohashi Y; Akiba T; Tsukamoto Y; Suzuki M
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous calcitriol on platelet intracellular calcium in uremic hemodialysis patients with secondary hyperparathyroidism.
    Lin SH; Shieh SD; Chyr SH; Lu KC; Lin YF; Diang LK; Chou TC; Ding YA
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Oct; 54(4):240-5. PubMed ID: 7982134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.